Money has gushed into the biotech industry over the last couple of years, as the pandemic brought the industry onto center stage. At the same time, tech investors have rushed into the arena.
Who has benefited the most?
STAT analyzed yearly financial records from more than four dozen biotech investment firms that laid out their assets, both in liquid cash and also biotech stock portfolios, to determine which have seen the most growth over time.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.